The recent introduction of ABP 501, an adalimumab biosimilar, in the treatment of rheumatic diseases was supported by a comprehensive comparability exercise with its originator. On the other hand, observational studies comparing adalimumab and ABP 501 in inflammatory arthritis are still lacking. The main aim of this study is to compare the clinical outcomes of the treatment with adalimumab, both the originator and ABP 501, in a large cohort of patients affected by autoimmune arthritis in a real life setting. We retrospectively analysed the baseline characteristics and the retention rate in a cohort of patients who received at least a course of adalimumab (originator or ABP 501) from January 2003 to December 2020. We stratified the study population according to adalimumab use: naive to original (oADA), naive to ABP 501 (bADA) and switched from original to ABP 501 (sADA). The oADA, bADA and sADA groups included, respectively, 724, 129 and 193 patients. In each group, the majority of patients had a diagnosis of rheumatoid arthritis. The total observation period was 9805.6 patient-months. The 18-month retentions rate in oADA, bADA and sADA was, respectively, 81.5%, 84.0% and 88.0% (p > 0.05). The factors influencing the adalimumab retention rate were an axial spondylarthritis diagnosis (Hazard Ratio (HR) 0.70; p = 0.04), switch from oADA to ABP 501 (HR 0.53; p = 0.02) and year of prescription (HR 1.04; p = 0.04). In this retrospective study, patients naive to the adalimumab originator and its biosimilar ABP 501 showed the same retention rate. Patients switching from the originator to biosimilar had a higher retention rate, even though not statistically significant, when compared to naive.

Becciolini, Andrea, Simone, Parisi, Rosalba, Caccavale, Elena, Bravi, Federica, Lumetti, Romina, Andracco, Alessandro, Volpe, Lucia, Gardelli, Francesco, Girelli, Eleonora, Di Donato, Daniele, Santilli, Gianluca, Lucchini, Maria Chiara, Ditto, Ilaria, Platè, Eugenio, Arrigoni, Flavio, Mozzani, Michele, Riva, Antonio, Marchetta, Enrico, Fusaro, Gilda, Sandri, Carlo, Salvarani, Marino, Paroli e Alarico, Ariani. "Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis" Working paper, MDPI, 2022. https://doi.org/10.3390/jpm12030335

Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis

Lumetti, Federica
Membro del Collaboration Group
;
Di Donato, Eleonora
Membro del Collaboration Group
;
Sandri, Gilda
Membro del Collaboration Group
;
Salvarani, Carlo
Membro del Collaboration Group
;
2022

Abstract

The recent introduction of ABP 501, an adalimumab biosimilar, in the treatment of rheumatic diseases was supported by a comprehensive comparability exercise with its originator. On the other hand, observational studies comparing adalimumab and ABP 501 in inflammatory arthritis are still lacking. The main aim of this study is to compare the clinical outcomes of the treatment with adalimumab, both the originator and ABP 501, in a large cohort of patients affected by autoimmune arthritis in a real life setting. We retrospectively analysed the baseline characteristics and the retention rate in a cohort of patients who received at least a course of adalimumab (originator or ABP 501) from January 2003 to December 2020. We stratified the study population according to adalimumab use: naive to original (oADA), naive to ABP 501 (bADA) and switched from original to ABP 501 (sADA). The oADA, bADA and sADA groups included, respectively, 724, 129 and 193 patients. In each group, the majority of patients had a diagnosis of rheumatoid arthritis. The total observation period was 9805.6 patient-months. The 18-month retentions rate in oADA, bADA and sADA was, respectively, 81.5%, 84.0% and 88.0% (p > 0.05). The factors influencing the adalimumab retention rate were an axial spondylarthritis diagnosis (Hazard Ratio (HR) 0.70; p = 0.04), switch from oADA to ABP 501 (HR 0.53; p = 0.02) and year of prescription (HR 1.04; p = 0.04). In this retrospective study, patients naive to the adalimumab originator and its biosimilar ABP 501 showed the same retention rate. Patients switching from the originator to biosimilar had a higher retention rate, even though not statistically significant, when compared to naive.
2022
Febbraio
Becciolini, Andrea; Parisi, Simone; Caccavale, Rosalba; Bravi, Elena; Lumetti, Federica; Andracco, Romina; Volpe, Alessandro; Gardelli, Lucia; Girelli...espandi
Becciolini, Andrea, Simone, Parisi, Rosalba, Caccavale, Elena, Bravi, Federica, Lumetti, Romina, Andracco, Alessandro, Volpe, Lucia, Gardelli, Francesco, Girelli, Eleonora, Di Donato, Daniele, Santilli, Gianluca, Lucchini, Maria Chiara, Ditto, Ilaria, Platè, Eugenio, Arrigoni, Flavio, Mozzani, Michele, Riva, Antonio, Marchetta, Enrico, Fusaro, Gilda, Sandri, Carlo, Salvarani, Marino, Paroli e Alarico, Ariani. "Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis" Working paper, MDPI, 2022. https://doi.org/10.3390/jpm12030335
File in questo prodotto:
File Dimensione Formato  
jpm-12-00335-v2.pdf

Open access

Descrizione: articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 515.29 kB
Formato Adobe PDF
515.29 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1269562
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact